Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

“…There is no relationship linking reduction in LDL cholesterol values and raised transaminases, and hypertransaminasemia is linked to statin dosage and physicochemical properties [240,241]. Moreover, statins improve symptom-free survival from cardiovascular disease selectively in those patients in whom coronary artery disease coexists with NAFLD [242].…”

Low Density Liproprotein Cholesterol Goal Levels in Cardiovascular Secondary Prevention

“…In J-Stars trial, [42] patients were treated with pravastatin 10 mg vs placebo. Initial LDL-C of the patients treated, was reduced in average in 21 mg/dl.…”

“…In PROVE-IT, the benefit analysis according to baseline LDL-C showed that is practically zero with values less than 100 mg / dl. [28,31,[38][39][40][41][42] As already noted, there is no detailed information as LDL-C baseline in the study TNT. [32] In addition, it should be noted that both the PROVE-IT and TNT average LDL-C values in the control group were close to 100 mg / dl, indicating that about 50% of these coronary patients were not meeting ATP III target LDL-C less than 100 mg / dl; then from these data cannot be concluded that this goal should be changed, but rather that must be achieved in all patients.…”

Lipid-lowering therapies and liver enzymes

“…In a meta-analysis of 9 trials, K. Dale reported a dose-related increased risk of elevated AST/ALT with statin therapy (risk ratio 3.1, 95% confidence interval 1.72-5.58 for high versus low intensity statin therapy) [12]. The frequency of aminotransferase elevation is 2/1000 patient-year with high doses and 1/1000 patient-year with low dose treatment [13].…”